Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges

Lipid-lowering therapies are widely used to prevent the development of atherosclerotic cardiovascular disease (ASCVD) and related mortality worldwide. “Omics” technologies have been successfully applied in recent decades to investigate the mechanisms of action of these drugs, their pleiotropic effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Gianazza, Erica, Brioschi, Maura, Iezzi, Ada, Paglia, Giuseppe, Banfi, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960554/
https://www.ncbi.nlm.nih.gov/pubmed/36834701
http://dx.doi.org/10.3390/ijms24043291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960554/
https://www.ncbi.nlm.nih.gov/pubmed/36834701
http://dx.doi.org/10.3390/ijms24043291

Ejemplares similares